ABAlice Bonanni

Alice Bonanni

*This is an algorithmically generated author record based on publicly available information.

Alice Bonanni has a total of 405 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • SP264THE KIDNEY IS THE MAJOR SITE FOR THE REGULATION OF SOLUBLE KLOTHO IN HUMANS

    by Daniela Picciotto, Daniela Verzola, Francesca Ansaldo, Samantha Milanesi, Emanuele Luigi Parodi, Gian Marco Rosa, Antonella Sofia, Alice Bonanni, Francesca Viazzi, Manrico Balbi, et al.

  • Anti-alpha-enolase antibodies in membranous nephropathy: isotype matters

    by Corrado Murtas, Maurizio Bruschi, Giovanni Candiano, Alice Bonanni, Gian Marco Ghiggeri


  • Urine proteome analysis in Dent's disease shows high selective changes potentially involved in chronic renal damage

    by Laura Santucci, Giovanni Candiano, Franca Anglani, Maurizio Bruschi, Enrica Tosetto, Daniela Cremasco, Luisa Murer, Chiara D'Ambrosio, Andrea Scaloni, Andrea Petretto, et al.


  • Open Access

    Urine Proteome Biomarkers in Kidney Diseases. I. Limits, Perspectives, and First Focus on Normal Urine

    by Laura Santucci, Maurizio Bruschi, Giovanni Candiano, Francesca Lugani, Andrea Petretto, Alice Bonanni, Gian Marco Ghiggeri

    Urine proteome is a potential source of information in renal diseases, and it is considered a natural area of investigation for biomarkers. Technology developments have markedly increased the power analysis on urinary proteins, and it is time to confront methodologies and results of major studies on the topics. This is a first part of a series of reviews that will focus on the urine proteome as a site for detecting biomarkers of renal diseases; the theme of the first review concerns methodological aspects applied to normal urine. Main issues are techniques for urine pretreatment, separation of exosomes, use of combinatorial peptide ligand libraries, mass spectrometry approaches, and analysis of data sets. Available studies show important differences, suggesting a major confounding effect of the technologies utilized for analysis. The objective is to obtain consensus about which approaches should be utilized for studying urine proteome in renal diseases.


  • Regulatory T Cells and Oxidative Stress in Minimal Change Nephropathy

    by Roberta Bertelli, Armando Di Donato, Alice Bonanni, Roberta Rossi, Pietro Ravani, Gian Marco Ghiggeri

  • Open Access

    Insulin sensitivity of muscle protein metabolism is altered in patients with chronic kidney disease and metabolic acidosis

    by Giacomo Garibotto, Antonella Sofia, Rodolfo Russo, Ernesto Paoletti, Alice Bonanni, Emanuele L. Parodi, Francesca Viazzi, Daniela Verzola


  • Open Access

    Regulatory T cells and minimal change nephropathy: in the midst of a complex network

    by R Bertelli, A Bonanni, A Di Donato, M Cioni, P Ravani, G M Ghiggeri

    Summary: Minimal change nephrosis (MCN) is an important cause of morbidity in children. In spite of successful therapies having been developed in the last three decades, most aspects related to pathogenesis still remain poorly defined. Evolution in basic immunology and results deriving from animal models of the disease suggest a complex interaction of factors and cells starting from activation of innate immunity and continuing with antigen presentation. Oxidants, CD80 and CD40/CD40L have probably a relevant role at the start. Studies in animal models and in human beings also suggest the possibility that the same molecules (i.e. CD80, CD40) are expressed by podocytes under inflammatory stimuli, representing a direct potential mechanism for proteinuria. B and T cells could play a relevant role this contest. Implication of B cells is suggested indirectly by studies utilizing anti-CD20 monoclonal antibodies as the main therapy. The role of regulatory T cells (Tregs) is supported mainly by results in animal models of nephrotic syndrome (i.e. adriamycin, puromycin, lipopolysaccharide), showing a protective effect of direct Treg infusion or stimulation by interleukin 2 (IL-2). Limited studies have also shown reduced amounts of circulating Tregs in patients with active MCN cells. The route from bench to bedside would be reduced if results from animal models were confirmed in human pathology. The expansion of Tregs with recombinant IL-2 and new anti-CD20 monoclonal antibodies is the beginning. Blocking antigen-presenting cells with cytotoxic T lymphocyte antigen (CTLA-4)–Ig fusion molecules inhibiting CD80 and/or with blockers of CD40–CD40 ligand interaction represent potential new approaches. The hope is that evolution in therapies of MCN could fill a gap lasting 30 years.


  • Open Access

    A Pilot Study of IL2 in Drug-Resistant Idiopathic Nephrotic Syndrome

    by Alice Bonanni, Roberta Bertelli, Roberta Rossi, Maurizio Bruschi, Armando Di Donato, Pietro Ravani, Gian Marco Ghiggeri

    Tregs infusion reverts proteinuria and reduces renal lesions in most animal models of nephrotic syndrome (i.e. Buffalo/Mna, Adriamycin, Promycin, LPS). IL2 up-regulates Tregs and may be an alternative to cell-therapy in this setting. To evaluate a potential role of IL2 as Tregs inducer and proteinuria lowering agent in human nephrotic syndrome we treated 5 nephrotic patients with 6 monthly cycles of low-dose IL2 (1x106 U/m2 first month, 1.5x106 U/m2 following months). The study cohort consisted of 5 children (all boys, 11–17 years) resistant to all the available treatments (i.e. steroids, calcineurin inhibitors, mycophenolate, Rituximab). Participants had Focal Segmental Glomerulosclerosis (3 cases) or Minimal Change Nephropathy (2 cases). IL2 was safe in all but one patient who had an acute asthma attack after the first IL2 dose and did not receive further doses. Circulating Tregs were stably increased (>10%) during the whole study period in 2 cases while were only partially modified in the other two children who started with very low levels and partially responded to single IL2 Proteinuria and renal function were not modified by IL2 at any phase of the study. We concluded that low-dose IL2 given in monthly pulses is safe and modifies the levels of circulating Tregs. This drug may not be able to lower proteinuria or affect renal function in children with idiopathic nephrotic syndrome. We were unable to reproduce in humans the effects of IL2 described in rats and mice reducing de facto the interest on this drug in nephrotic syndrome. ClinicalTrials.gov NCT02455908


  • Low-dose ofatumumab for rituximab-resistant nephrotic syndrome

    by Alice Bonanni, Roberta Rossi, Corrado Murtas, Gian Marco Ghiggeri

    Drug resistant idiopathic nephrotic syndrome (DRNS) remains a therapeutic dilemma. In this pilot study, the efficacy of the new fully humanised, anti-CD20 monoclonal antibody ofatumumab was tested in 4 children with persistence of proteinuria for at least 12 months in spite of a full drug approach (including rituximab). We used a low-dose 2-infusion ofatumumab model (300+700 mg/1.73 m2 2 weeks apart) using specified premedication. Transient normalisation of proteinuria (persisting for 2 months) was achieved in 1 child while another presented stable remission after 12 months; both had normal renal function. The outcome was not modified in the remaining 2 children presenting an impaired renal function. These results demonstrate that low-dose ofatumumab may induce remittance of proteinuria in children with a long story of DRNS and normal renal function. Further studies are needed to test whether higher doses of ofatumumab can also modify proteinuria in patients with impaired renal function.


  • Open Access

    Rituximab in Children with Steroid-Dependent Nephrotic Syndrome

    by Pietro Ravani, Roberta Rossi, Alice Bonanni, Robert R. Quinn, Felice Sica, Monica Bodria, Andrea Pasini, Giovanni Montini, Alberto Edefonti, Mirco Belingheri, et al.

    Steroid-dependent nephrotic syndrome (SDNS) carries a high risk of toxicity from steroids or steroid-sparing agents. This open-label, noninferiority, randomized controlled trial at four sites in Italy tested whether rituximab is noninferior to steroids in maintaining remission in juvenile SDNS. We enrolled children age 1–16 years who had developed SDNS in the previous 6–12 months and were maintained in remission with high prednisone doses (≥0.7 mg/kg per day). We randomly assigned participants to continue prednisone alone for 1 month (control) or to add a single intravenous infusion of rituximab (375 mg/m2; intervention). Prednisone was tapered in both groups after 1 month. For noninferiority, rituximab had to permit steroid withdrawal and maintain 3-month proteinuria (mg/m2 per day) within a prespecified noninferiority margin of three times the levels among controls (primary outcome). We followed participants for ≥1 year to compare risk of relapse (secondary outcome). Fifteen children per group (21 boys; mean age, 7 years [range, 2.6–13.5 years]) were enrolled and followed for ≤60 months (median, 22 months). Three-month proteinuria was 42% lower in the rituximab group (geometric mean ratio, 0.58; 95% confidence interval, 0.18 to 1.95 [i.e., within the noninferiority margin of three times the levels in controls]). All but one child in the control group relapsed within 6 months; median time to relapse in the rituximab group was 18 months (95% confidence interval, 9 to 32 months). In the rituximab group, nausea and skin rash during infusion were common; transient acute arthritis occurred in one child. In conclusion, rituximab was noninferior to steroids for the treatment of juvenile SDNS.